Robot model
ROSA
ROSA, the Robotic Surgical Assistant, is Zimmer Biomet's surgeon-controlled robotic-arm platform, recorded in the surgical form factor as the mid-size,…
- Manufacturer
- Zimmer Biomet
- Form factor
- surgical
- Maturity
- commercial
- Lifecycle
- active
- Deployments
- 2
- Website
- investor.zimmerbiomet.com ↗
Overview
ROSA, the Robotic Surgical Assistant, is Zimmer Biomet's surgeon-controlled robotic-arm platform, recorded in the surgical form factor as the mid-size, multi-procedure archetype of the orthopedic sub-cohort and the one that crosses surgical sub-domains, spanning orthopedics and neurosurgery from a single robotic-arm and navigation architecture. The arm is coupled to optical navigation and two- and three-dimensional planning software and positions or guides instruments, but it moves only on surgeon command and does not cut or place autonomously, so ROSA is AI-augmented surgeon-controlled assistance rather than autonomous surgery and is in scope as a surgical robot. Made by Zimmer Biomet Holdings, listed on the New York Stock Exchange as ZBH and headquartered in Warsaw, Indiana, ROSA originated at the French company Medtech SA, founded in 2002 in Montpellier by Bertin Nahum, which built ROSA Brain and ROSA Spine; Zimmer Biomet acquired Medtech SA in 2016 at fifty euros per share and extended the ROSA arm into orthopedics. The current Zimmer Biomet variants are ROSA Knee for total knee arthroplasty, cleared January 25, 2019 and enhanced as ROSA Knee with OptimiZe cleared November 14, 2025, ROSA Hip for direct anterior total hip arthroplasty cleared August 18, 2021, ROSA ONE Brain for cranial neurosurgery including biopsy, stereo-electro-encephalography, deep brain stimulation, and ventricular and transnasal endoscopy cleared February 11, 2019, and ROSA Shoulder for shoulder arthroplasty cleared in February 2024. ROSA ONE Spine, cleared in 2019, left Zimmer Biomet in the March 2022 ZimVie spinoff and is no longer a Zimmer Biomet product. A registry nuance worth recording is that autonomy enters Zimmer Biomet's portfolio separately through its Monogram Technologies acquisition, completed October 7, 2025, which brings a CT-based semi-autonomous total-knee robot and a fully-autonomous version in development; this is kept distinct from ROSA, whose surgeon-controlled status is unchanged. Installed-base figures circulating in aggregators conflict and none is asserted here.
Verified vs. claimed
- Maturity stage
- commercial(Commercially deployed with revenue-generating operations.)
- Verified deployments
- 2 deployments on file
- Sources on file
- 8 sources, view all
Key facts
Autonomy level
Drive type
Form factor
ROSA Knee clearance date
ROSA Hip clearance date
Price
Availability
Pricing model
Specs
Arms
Notes
Specs
Weight kg
Form Factor
Fda clearance
Visualization
Procedure types
Data & sources
Company filings
1
Press releases
3
Research
1
Web sources
3
8 sources backing this record.View all →
Availability and pricing
- Availability
- Not sold (internal use)
- Price
- $1M to $1.5M (analyst estimate)as of 2025-01-01
- Units in field
- Not disclosed
- Sales model
- Not disclosed
- Lead time
- Not disclosed
Pricing
One-time purchase
$1,000,000 - $1,500,000 USDanalyst estimateas of 2025-01-01
Source: How Much is a Surgical Robot? (2025 Edition) – R2 Surgical
Price status: actual-sale-price = real published price at time of sale; manufacturer-target = vendor target, not yet realized; analyst-estimate = third-party projection, not a vendor figure; not-announced = no price on record.
Prices verified as of Jan 1, 2025
Deployments (2)
- ROSA at Franceoperational
ROSA surgical systems have approximately 100 or more installations across Europe, with an active CE mark covering ROSA Knee and Hip applications.
- ROSA at United Statesoperational
ROSA surgical robots have been installed across approximately 500+ systems in the United States, with FDA clearances for knee (2019), hip (2021), and shoulder (2024) replacement procedures.
ROSA on the deployment map
Where ROSA is verified operating. Explore the deployment map by place and type.
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Superseded updatedJul 11, 2026
medtech-sa-rosa -> zimmer-biomet-rosa
- Verified media addedVerifiedJun 5, 2026
Zimmer Biomet ROSA Knee System
- Record createdJun 4, 2026
Added to the verified registry
- Price point recorded: $1,000,000-$1,500,000Jan 1, 2025
Analyst estimate
- Incident recordedSep 22, 2021
Zimmer Biomet ROSA ONE Brain 3.1 Class I recall: software could drive instruments to a...
Previous generation
- ROSAsuperseded
The historical entries remain on the registry for reference; current coverage tracks this generation.
Deployment-verified media (1)
Zimmer Biomet's patient explainer for its ROSA Knee system (the knee variant, for total knee arthroplasty). A surgeon-controlled robotic assistant for bone-cut guidance, not autonomous.
From deployment: United States
Components (1)
Navigation / trajectory control
- software fault · critical: FDA Class I recall; software correction for trajectory error.
Components carry componentClass + safetyCritical flag. ModelComponent rows carry safety_role (primary_safety / backup_safety / monitoring / non_safety) + optional supplier identity.
Regulatory filings (3)
- fda_recallfda recall · us_fdarecalled2021-09-22
Applicant: Zimmer Biomet
- fda_510kfda 510k · us_fdacleared2019-01-01
Applicant: Zimmer Biomet
- K182964fda 510k · us_fdacleared2018-10-25
Applicant: Zimmer Biomet
Safety record
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Incidents affecting ROSA (1)
Includes incidents linked directly to this model or to deployments of it. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.
Sources (8)
- https://investor.zimmerbiomet.com/news-and-events/news/2019/01-25-2019-140357749
- https://investor.zimmerbiomet.com/news-and-events/news/2021/08-18-2021-133112714
- https://www.prnewswire.com/news-releases/zimmer-biomet-receives-us-fda-clearance-for-enhanced-version-of-rosa-knee-robotic-technology-302615106.html
- https://www.meddeviceonline.com/doc/zimmer-biomet-fda-clearance-rosa-one-brain-application-0001
- https://www.sec.gov/Archives/edgar/data/0001136869/000119312516649891/d223411dex991.htm
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7465763/
- https://www.prnewswire.com/news-releases/zimmer-biomet-completes-acquisition-of-monogram-technologies-302577035.html
- https://www.zimmerbiomet.com/content/dam/zb-corporate/en/products/smart-orthopedics/robotics/rosa-hip-system/3500.6-GLBL-en%20ROSA%20Hip%20System%20User%20Manual%20and%20Surg%20Tech%20V1.1-digital.pdf
Compare ROSA
Common questions
- What is ROSA?
- ROSA, the Robotic Surgical Assistant, is Zimmer Biomet's surgeon-controlled robotic-arm platform, recorded in the surgical form factor as the mid-size, multi-procedure archetype of the orthopedic sub-cohort and the one that crosses surgical sub-domains, spanning orthopedics and neurosurgery from a single robotic-arm and navigation architecture. The arm is coupled to optical navigation and two- and three-dimensional planning software and positions or guides instruments, but it moves only on surgeon command and does not cut or place autonomously, so ROSA is AI-augmented surgeon-controlled assistance rather than autonomous surgery and is in scope as a surgical robot. Made by Zimmer Biomet Holdings, listed on the New York Stock Exchange as ZBH and headquartered in Warsaw, Indiana, ROSA originated at the French company Medtech SA, founded in 2002 in Montpellier by Bertin Nahum, which built ROSA Brain and ROSA Spine; Zimmer Biomet acquired Medtech SA in 2016 at fifty euros per share and extended the ROSA arm into orthopedics. The current Zimmer Biomet variants are ROSA Knee for total knee arthroplasty, cleared January 25, 2019 and enhanced as ROSA Knee with OptimiZe cleared November 14, 2025, ROSA Hip for direct anterior total hip arthroplasty cleared August 18, 2021, ROSA ONE Brain for cranial neurosurgery including biopsy, stereo-electro-encephalography, deep brain stimulation, and ventricular and transnasal endoscopy cleared February 11, 2019, and ROSA Shoulder for shoulder arthroplasty cleared in February 2024. ROSA ONE Spine, cleared in 2019, left Zimmer Biomet in the March 2022 ZimVie spinoff and is no longer a Zimmer Biomet product. A registry nuance worth recording is that autonomy enters Zimmer Biomet's portfolio separately through its Monogram Technologies acquisition, completed October 7, 2025, which brings a CT-based semi-autonomous total-knee robot and a fully-autonomous version in development; this is kept distinct from ROSA, whose surgeon-controlled status is unchanged. Installed-base figures circulating in aggregators conflict and none is asserted here.
- How much does ROSA cost?
- ROSA is listed at $1,000,000 to $1,500,000 on the DEPLOY registry. This is an analyst estimate, not an official price.
- Is ROSA actually deployed in the real world?
- Yes. ROSA is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.
- Is ROSA autonomous or teleoperated?
- Not verified as fully autonomous. ROSA's capabilities on the DEPLOY registry are recorded as teleoperated-assisted, demonstrated-only, or vendor claims (Assists surgery), not independently confirmed to run without a human in the loop.
- Where is ROSA deployed?
- 2 verified deployments of ROSA are on the DEPLOY registry, including at France, United States.
- Can you buy ROSA?
- ROSA is in commercial deployment and is sold to operators; contact the manufacturer to buy, and see the pricing section for any recorded price.
- Is ROSA FDA cleared?
- ROSA has 3 regulatory records on the DEPLOY registry: FDA recall, recalled; FDA 510(k) clearance, cleared; FDA 510(k) clearance (K182964), cleared. See the Regulatory filings section for each agency source.
- What are alternatives to ROSA?
- On the DEPLOY registry, comparable surgical robots to ROSA include Toumai, da Vinci (and Ion), Epione, Hugo RAS.
- How does ROSA compare to Toumai?
- ROSA and Toumai (MicroPort MedBot · 8 deployments) are both surgical robots on the DEPLOY registry. ROSA has 2 verified deployments on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.
- Is ROSA a top surgical?
- On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, ROSA ranks in roughly the top 38% of surgical models tracked by the registry.
- What is ROSA's maturity stage?
- ROSA is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.
- Is ROSA safe?
- ROSA has 1 active incident on record in the DEPLOY registry. 1 recall on record (1 critical). Most recent: Sep 2021. Retracted incidents are excluded from this count.
- How does ROSA compare to Stryker Mako for knee replacement?
- Neither Mako nor ROSA is clearly superior, according to industry analysts. Mako features a robotic arm with a bone saw and emphasizes haptic feedback. ROSA uses a cutting guide approach. Both are FDA-cleared for robotic-assisted knee replacement. Mako has over 1 million completed procedures; ROSA has multiple indications (knee, hip, brain, shoulder) with a Class I recall on the brain version.
Methodology: Aggregator drift detected · 8 sources (5 primary) · last reviewed 2026-07-15
Verification posture
Aggregator drift detected
Cap-flag required
Review state
Drift-flagged
Last reviewed 2026-07-15
1 anchored drift pattern(s); see cap_flags
Maturity + lifecycle
Maturity stage: commercial
Lifecycle: active
Architectural position
Cohort: surgical
Sources by quality tier
- 3
- primary-company-ir
- Company IR disclosure
- 3
- unclassified
- Unclassified source
- 1
- primary-sec-filing
- SEC filing
- 1
- primary-academic-peer-reviewed
- Peer-reviewed clinical / academic
Canonical worked example pair
Surgical orthopedic robot sub-cohort triangle
This entity is the knee-only post-ZimVie-spin-off anchor on within-cohort-verified-vs-claimed-pair.
Pairs with: stryker-mako, smith-nephew-cori
Cap flags
Claim: Zimmer Biomet ROSA Spine is a current ROSA variant
Honest status: ROSA Spine left Zimmer Biomet in the 2022 ZimVie spin-off and is not a current ZB ROSA variant. Current ZB ROSA scope is knee + hip; spine moved with ZimVie.
ROSA Spine departed Zimmer Biomet via 2022 ZimVie spin-off. Current ZB ROSA is knee + hip only.
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for ROSA.Recent coverage
ROSA in third-party press
Attention vs reality over time
Media mentions per month (area) against verified deployment events (dots). A press spike over a flat deployment line is the hype gap, drawn over time.
In the press
Recent coverage mentioning ROSA from third-party publications. Automatically surfaced; not part of the verified registry record.
Zimmer Biomet to Hire 500 in India as New Bengaluru Technology Centre Drives AI and MedTech Innovation
Zimmer Biomet will hire 500 professionals over the next three years for its new Bengaluru technology centre, expanding its AI, software engineering, and R&D capabilities as India…
Calian for Resilient GNSS, From Water to Space
Readers will not be surprised to learn resilience was a major focus at Eurosatory 2026. Across giant exhibit halls packed with the latest... The post Calian for Resilient GNSS,…
Tank maker KNDS plans stock market listing, Germany to buy 40% stake
The firm showed a proposed battle tank at Eurosatory defense exhibition in Paris boasting a French turret and gun mounted on a German Leopard 2 chassis.
Redwire Unveils Upgraded Octopus E140 MWIR EO/IR Payload at Eurosatory, Combining Long-Range Performance, Precision Geolocation, and All-Weather Capabilities
Redwire’s upgraded Octopus E140 MWIR is a next-generation gyrostabilized Electro-Optical/Infrared (EO/IR) aircraft payload that delivers advanced intelligence, surveillance, and…
Redwire Announces Octopus E180 HD MWIR at Eurosatory 2026, Expanding Mission-Ready, High-Definition ISR Capabilities with 4K Resolution
Redwire is proud to announce the launch of our Octopus E180 HD MWIR, a next-generation gyro-stabilized Electro-Optical/Infrared (EO/IR) aircraft payload that combines…
Zimmer Biomet and PeritasAI Collaborate to Explore Agentic Connected Robotics for a Smarter Unified Operating Room
PeritasAI is collaborating with Zimmer Biomet to explore agentic connected robotics powered by NVIDIA Physical AI infrastructure, creating a smarter unified operating room where…
FDA puts Class I label on Zimmer Biomet ROSA Brain robot recall
FDA Class I recall for ROSA Brain 3.0. Software anomaly causes robotic arm to move to incorrect position during neurosurgery. 86 units affected.
ROSA Neurosurgery Device Recalled Due to Software Issue
FDA Class I recall for Zimmer Biomet ROSA Brain device. Software issue drives robotic arm to incorrect position during neurosurgery.
Oshkosh Defense Highlights Proven, Adaptable Tactical Mobility Solutions for Europe at Eurosatory 2026
PARIS, FRANCE: As European and allied forces accelerate modernization efforts in response to evolving operational threats, Oshkosh Defense LLC, an Oshkosh Corporation [NYSE: OSK]…
Redwire to Showcase UAS and ISR Capabilities at Eurosatory 2026
The Redwire team will be in Paris, France from June 15-19 for Eurosatory 2026 to connect with international government, military, and industry and explore the growing…
Zimmer pays at least $132m for French robot-assisted surgery firm Medtech
Zimmer Biomet acquired French surgical robotics company Medtech SA, maker of the ROSA surgical robot, for at least $132 million.
Machine-readable surfaces
- Markdown mirror: /models/zimmer-biomet-rosa.md
- JSON-LD: embedded in this page’s head
- REST API: /v1/models/deb70c72-adc4-4912-b3f3-cddee712e118
- Revision history: /models/zimmer-biomet-rosa/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Buyer-facing pricing: deploy.report/price/zimmer-biomet-rosa
Reality vs attention
ROSA draws attention at the 60th percentile but verifies reality at the 71st percentile among surgical robots. Hype Gap -11, 17th widest among surgical robots.
6-month trend
Analysis
Thin deployment record; scale validation still in progress.
Signal flags
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Jul 19, 2026